Cancer Research UK logo.
SearchDonate
  • Search

A study looking at personalised prehabilitation for myeloid leukaemia and myelodysplastic syndrome (PROPEL)

Overview

Cancer types:

Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia, Myelodysplastic syndrome (MDS)

Status:

Open

Phase:

Other

Details

This study is assessing the value of prehabilitation for people with acute myeloid leukaemia and myelodysplastic syndrome.

It is open to people who have:

  • acute myeloid leukaemia (AML) with no sign of their leukaemia after initial (induction) chemotherapy

  • AML that has come back and after further treatment there is no sign of their leukaemia

  • myelodysplastic syndrome (MDS) that has excess blast cells

Recruitment start: 29 September 2023

Recruitment end: 31 March 2026

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Janet Dunn

Professor Simon Stanworth

Supported by

NIHR Evaluation Trials and Studies Coordinating Centre (NETSCC)

National Institute of Health and Research: Health Technology Assessment programme

University of Warwick

University Hospitals Coventry and Warwickshire

Last reviewed: 08 Jan 2026

CRUK internal database number: 19382

Help and support